-
UPDATE: RBC Capital Downgrades BioCryst Pharma (BCRX) to Sector Perform
-
BioCryst Pharma (BCRX) PT Raised to $16 at RBC Capital; Sees Continued Upside
-
BioCryst Pharma (BCRX) PT Raised to $10 at RBC Capital
-
BioCryst Pharma (BCRX) PT Raised to $9 at RBC Capital
-
BioCryst (BCRX) Seen as Undervalued Pure-Play Late-Stage Orphan Co. - RBC
-
BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at Two Upcoming Healthcare Investor Conferences
-
Pre-Open Movers 01/02: (NETE) (WATT) (AKAO) Higher; (WFT) (TSRO) (MLCO) Lower (more...)
-
RBC Capital Upgrades BioCryst Pharma (BCRX) to Outperform, Sees Attractive Point at Current Valuation Level
-
RBC Capital Starts BioCryst Pharma (BCRX) at Sector Perform
-
Pre-Open Movers 01/27: (LOXO) (DVAX) (FOR) Higher; (INSY) (HLF) (PRGO) Lower (more...)
-
Notable Analyst Rating Changes 6/30: (BCRX) (ING) (RRC) Upgraded; (NI) (APOL) (ANF) Downgraded
-
Pre-Open Stock Movers 06/30: (JUNO) (WSH) (PNR) Higher; (ETRM) (APOL) (SNE) Lower (more...)
-
Notable Analyst Rating Changes 08/08: (ATVI) (ABX) (DK) Upgraded; (MYL) (HIBB) (SSYS) Downgraded
-
Notable Analyst Rating Changes 03/10: (BIG) (ADM) (X) Upgraded; (SPLS) (O) (TMHC) Downgraded
-
Notable Analyst Rating Changes 02/21: (PAAS) (STX) (SIG) Upgraded; (GRPN) (WMT) (PHG) Downgraded
-
Notable Analyst Rating Changes 02/20: (TMO) (NBR) (ABX) Upgraded; (AAPL) (FB) (SM) Downgraded
-
Notable Analyst Rating Changes 01/28: (FTNT) (MLM) (MT) Upgraded; BHI) (BCRX) (HIMX) Downgraded
-
Notable Analyst Rating Changes 11/12: (XTEX) (LF) (BCRX) Upgraded; (SRPT) (GOGO) (CLH) Downgraded
-
Notable Analyst Rating Changes 1/29: WMT, BCR, MAN, URBN, ARBA Upgraded; FII, BHLB, KSP Downgraded
-
Morning Movers 4/29: DNDN, DWA, MSPD, PFWD, PSYS Higher; ETFC, BCRX, ROC, BLDP, SSYS Lower